Department of Emergency Medicine, University of Iowa Carver College of Medicine, Iowa City, IA, USA.
COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia.
Hum Vaccin Immunother. 2023 Dec 15;19(3):2284471. doi: 10.1080/21645515.2023.2284471. Epub 2023 Nov 23.
COVID-19 vaccination is effective at reducing SARS-CoV-2 complications, but uptake has been low. Our objective in this study was to compare the importance of factors reported to influence the decision to receive a bivalent COVID-19 booster vaccine among health care personnel (HCP) tested for SARS-CoV-2 between October 2022 and April 2023 in a 20-hospital vaccine effectiveness study in the United States ( = 1656). Compared with those who had not received the booster, the factors most likely to be reported to be important were concerns about contracting COVID-19 (84.0% of those who had received the bivalent booster vs. 47.5% of those who had not, difference 36.6% points (PP), 95% confidence interval [CI] 32.1 to 41.1%), spreading infection to family members (89.2% vs. 62.8%, difference 26.3 PP, 95% CI 22.3 to 30.4%), and spreading infection to colleagues at work (85.5% vs. 59.4%, difference 26.1 PP, 95% CI 21.7 to 30.5%). HCP who had received the booster more frequently cited the primary literature (61.7% vs. 31.8%, difference 29.9 PP, 95% CI 24.6 to 35.2%) and employer recommendations (48.3% vs. 29.8%, difference 18.5 PP, 95% CI 13.2 to 23.9%) as influencing their decision. This analysis provides insight into factors for targeting future vaccine messaging.
COVID-19 疫苗接种可有效降低 SARS-CoV-2 并发症，但接种率一直较低。我们的研究目的是比较 2022 年 10 月至 2023 年 4 月期间在美国 20 家医院进行的 COVID-19 疫苗效力研究中接受 SARS-CoV-2 检测的医护人员（HCP）报告的影响接种 bivalent COVID-19 加强针的因素的重要性 = 1656）。与未接种加强针的人相比，最有可能被报告为重要的因素是担心感染 COVID-19（接种 bivalent 加强针的人中 84.0%，未接种的人中 47.5%，差异 36.6%点（PP），95%置信区间[CI] 32.1 至 41.1%），将感染传播给家庭成员（接种 bivalent 加强针的人中 89.2%，未接种的人中 62.8%，差异 26.3%PP，95%CI 22.3 至 30.4%），以及将感染传播给工作中的同事（接种 bivalent 加强针的人中 85.5%，未接种的人中 59.4%，差异 26.1%PP，95%CI 21.7 至 30.5%）。接种加强针的 HCP 更频繁地引用主要文献（61.7%，而 31.8%，差异 29.9%PP，95%CI 24.6 至 35.2%）和雇主建议（48.3%，而 29.8%，差异 18.5%PP，95%CI 13.2 至 23.9%）作为影响他们决策的因素。这项分析提供了对未来疫苗信息目标因素的洞察。
